STAT+: Tracking the FDA advisory panel on Eisai and Biogen’s treatment for Alzheimer’s disease
The Food and Drug Administration is convening a meeting of outside experts on Friday to…
Category: STAT+
STAT+: Top Senate Republican signals interest in site-neutral reform for hospitals
WASHINGTON — A top Senate Republican signaled his interest in pursuing hospital payment reform to…
STAT+: Study finds supplements of amino acid taurine slow aging in mice and monkeys
The first clue was blind cats. About 50 years ago, K.C. Hayes, a professor of…
STAT+: If AI invents a new medicine, who gets the patent?
Pharmaceutical and biotech companies are increasingly using artificial intelligence to discover and make drugs and…
.jpg)
STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits
Rise and shine, everyone, another busy day is on the way, although the smoky covering…
STAT+: After gene therapy deaths, Astellas brings in potentially safer treatment for muscle disorder
Astellas Pharma said Thursday it will license and develop a new gene therapy for a…
STAT+: Democrats blast Biden administration over Alzheimer’s drug plans
WASHINGTON — Ahead of a major Food and Drug Administration meeting on a new Alzheimer’s…
STAT+: ‘We don’t agree’ on drug pricing policy, FDA chief tells biotech leaders
BOSTON — The drug industry has spent the past year speaking against new mechanisms that…
STAT+: After missing vaccine glory in pandemic, GSK looks to dominate other diseases
BOSTON — GSK has been developing vaccines under one corporate guise or another for 140…
STAT+: While other states, countries have biotech envy, Massachusetts can’t find enough workers
While other states and nations came to the global BIO 2023 convention in Boston this…
STAT+: Pharmalittle: U.K. launches pilot to expand access to weight loss drugs; European Union approves RSV vaccine
Top of the morning to you, and a fine one it is. Well, sort of….
STAT+: Google strikes deal with Mayo Clinic to comb patient records using generative AI
Google will embed its generative AI technology into computer systems at Mayo Clinic and other…
STAT+: ASCO showcased the payoff for new cancer medicines: longer lives
CHICAGO — Well, that’s a wrap. The biggest meeting in cancer research — and, really,…
.jpg)
STAT+: Buoyed by cancer advances, new ASCO president also stresses honest prognosis
CHICAGO — As a busy weekend at the American Society of Clinical Oncology annual meeting…
STAT+: With digital therapeutics businesses flailing, the industry descends on D.C. to make the case for coverage
This week, the leading advocacy group for digital therapeutics companies is gathering the industry’s leaders…
STAT+: FDA will allow troubled chemotherapy maker to resume distribution of cancer drugs in short supply
After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy…
STAT+: Biotech’s trade secrets face growing threat from foreign influences, science leaders warn
BOSTON — While most panel discussions at the Biotechnology Innovation Organization’s international convention tend to…
STAT+: Pharmalittle: Merck sues U.S. to halt Medicare drug-price negotiation; FDA oncology head wants advisory panels to keep voting on new drugs
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain
CHICAGO — A medical device made by Novocure that creates electric fields in the lungs…
STAT+: Medicare taps acting official to head up its new drug price negotiations
WASHINGTON — Medicare has chosen a Center for Medicare and Medicaid Innovation official to temporarily…
STAT+: The woman behind AstraZeneca’s cancer winning streak
CHICAGO — It was the kind of moment scientists who develop new medicines wait their…
STAT+: More than 200 FDA staffers have retired in less than a year
WASHINGTON — More than 230 people have retired from the Food and Drug Administration since…
STAT+: FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer’s advisory panel
The Food and Drug Administration has removed a neurologist with financial ties to Biogen and…
STAT+: FDA oncology head wants advisory panels to keep voting on new drugs
CHICAGO — As commissioner of the Food and Drug Administration, Robert Califf has made clear…
STAT+: UnitedHealth starts bidding war with $3.3 billion offer for Amedisys
There’s now a two-party showdown for one of the largest home health companies in the…
STAT+: Ted Love, BIO’s first Black board chair, aims to rehab biotech’s image in Washington
WASHINGTON — Ted Love has pretty much done everything there is to do in biotech. He’s…
STAT+: Gilead’s CAR-T therapy prolongs survival in key blood cancer trial
CHICAGO — Yescarta, the CAR-T therapy made by the Kite unit of Gilead Sciences, prolonged…
STAT+: Bellerophon Therapeutics trial fails despite innovative digital endpoint
In an important reminder that plugging digital tools into a clinical trial will not magically…
STAT+: Carbon Health is already using AI to write patient records
SAN FRANCISCO — Primary care tech startup Carbon Health is using artificial intelligence to listen…
STAT+: Pharmalittle: AstraZeneca lung cancer drug halves death risk; 400 Grail patients incorrectly told they may have cancer
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: To push antibiotic makers to be more green, a new system will certify manufacturing practices
In response to concerns about pollution caused by antibiotic production, an industry group is launching…
STAT+: How Blue Cross Blue Shield insurers ratcheted up profits in 2022
A $203 million tax refund for Blue Cross Blue Shield of North Carolina. Nearly $1.5…
STAT+: Keytruda’s benefits, a breast cancer win, the ‘dom-zim doublet’: Weekend wrap-up from ASCO
CHICAGO — The annual meeting of the American Society of Clinical Oncology is back in…
STAT+: Biotechs face challenges as the industry’s annual bash returns to Boston
The world has changed since 2018 when the Biotechnology Innovation Organization last brought its annual…
STAT+: ‘Extraordinary’ survival data for lung cancer patients is seen as boost for AstraZeneca drug
CHICAGO – Giving the AstraZeneca drug Tagrisso to patients with non-small cell lung cancer who…
STAT+: Targeted drug greatly slows progression of a brain cancer
CHICAGO – An experimental drug dramatically slowed the growth of glioma, a type of brain…
STAT+: Pharmalittle: Medicare holds firm on Alzheimer’s drug coverage policy; Pfizer says antibiotic combo can treat some superbugs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Novartis drug reduces breast cancer recurrence, but experts may debate results
Kisqali, a breast cancer pill made by Novartis, reduced the risk of recurrence of the…
STAT+: Pharmalittle: Coherus undercuts AbbVie with discounted Humira; FDA approves second RSV vaccine
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on the back half…
STAT+: Tempus launches an AI ‘assistant’ for thousands of oncologists
Tempus, a company that combines DNA sequencing for cancer with artificial intelligence, said Thursday that…
STAT+: Coherus works with Mark Cuban to sell biosimilar Humira at steep discounts
In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira —…
STAT+: Debt ceiling deal could mean cancer, disease research cuts, advocates warn
WASHINGTON — Researchers and health care advocates are warning that the debt ceiling deal would…
STAT+: Republicans want to crack down on pricey health regulations, but there are major loopholes
WASHINGTON — At first glance, the debt ceiling deal that Republicans struck with the White…
Hospitals want to buy doctors’ happiness with Nuance’s AI scribe. What they’re paying varies
Microsoft-owned Nuance Communications sells its AI medical scribe platform to health care providers on a…
STAT+: CVS warns PBM reforms ‘could lead to higher costs’
As Congress considers wide-ranging reforms to pharmacy benefit managers, a top executive at CVS Health,…
STAT+: Pharmalittle: Appeals court rules Purdue can shield Sacklers from lawsuits; chemo shortage blamed on drugmakers’ lack of investment
Hey there. STAT reporter Andrew Joseph here welcoming you to Wednesday’s edition of Pharmalittle, with…
STAT+: Pharmalittle: Pfizer touts study data for hemophilia drug; former Novartis execs cleared of bribery in Greece
Good morning, everyone, and how are you today? We are doing find, thank you, especially…
STAT+: European regulatory panel weighing against approval of Amylyx’s ALS therapy, company says
LONDON — A European regulatory panel has taken a negative view of whether an ALS…
STAT+: Lured by a bigger payday, a medical device maker sold fake plastic parts. Many were implanted in chronic pain patients
Stimwave’s pitch was alluring. As a startup tackling chronic pain with nerve-stimulating devices, it promised…
STAT+: Neuralink can now study its brain implant in humans, but it’s still catching up to its peers
Neuralink can now study its brain implant in humans after securing a go-ahead from the…